1. 18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial. (13th November 2020) Authors: Harter, P; Petran, D; Scambia, G; Ortega, E; Tsibulak, I; Nagao, S; Vergote, I; Meunier, J; Priou, F; Sverdlin, R; Milenkova, T; Ray-Coquard, I; Ray-Coquard, I Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial. (18th September 2019) Authors: Penson, RT; Valencia, RV; Cibula, D; Colombo, N; III, CL; Bidzinski, M; Kim, JW; Nam, JH; Madry, R; Hernández, CH; Mora, P; Ryu, SY; Milenkova, T; Lowe, e; Barker, L; Scambia, G Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗